Table 1.
Clinical manifestation of 65 patients with advanced hepatobiliary cancers receiving anti-programmed cell death protein 1 treatment
| Characteristics | Total (n=65) |
CBR (n=32) |
NCB (n=33) |
P value |
| Sex | ||||
| Male | 46 | 25 | 21 | 0.277 |
| Female | 19 | 7 | 12 | |
| Age (years) | ||||
| ≤60 | 34 | 18 | 16 | 0.622 |
| >60 | 31 | 14 | 17 | |
| Hepatitis | ||||
| Yes | 32 | 14 | 18 | 0.460 |
| No | 33 | 18 | 15 | |
| Child-Pugh score | ||||
| 5 | 45 | 22 | 23 | 0.901 |
| 6 | 9 | 4 | 5 | |
| 7 | 11 | 6 | 5 | |
| ECOG-PS | ||||
| 0 | 44 | 22 | 22 | >0.999 |
| 1 | 21 | 10 | 11 | |
| Bilirubin level | ||||
| Elevated | 8 | 4 | 4 | >0.999 |
| Normal | 57 | 28 | 29 | |
| Bile acid level | ||||
| Elevated | 21 | 10 | 11 | >0.999 |
| Normal | 44 | 22 | 22 | |
| Tumor type | ||||
| HCC | 30 | 17 | 13 | 0.267 |
| BTC | 35 | 15 | 20 | |
| Tumor number | ||||
| Single | 28 | 14 | 14 | >0.999 |
| Multiple | 37 | 18 | 19 | |
| Tumor size (cm) | ||||
| <5 | 33 | 17 | 16 | 0.806 |
| ≥5 | 32 | 15 | 17 | |
| Stage | ||||
| II | 6 | 3 | 3 | 0.993 |
| III | 26 | 13 | 13 | |
| IV | 33 | 16 | 17 |
BTC, biliary tract cancer; CBR, clinical benefit response; ECOG-PS, Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; NCB, non-clinical benefit.